☆ 4.7 Article

Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records

JAMA NETWORK OPEN (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Health Care Sciences & Services

Mapping each pre-existing condition's association to short-term and long-term COVID-19 complications

Aj Venkatakrishnan et al.

Summary: Analyzing clinical notes from 1803 hospitalized COVID-19 patients using deep neural network models, it was found that hypertension is the most significant risk factor associated with multiple complications, providing a basis for the development of risk assessment scores for guiding clinical care pathways.

NPJ DIGITAL MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Rachna T. Shroff et al.

Summary: Cancer patients showed diminished immune responses to the BNT162b2 mRNA vaccine compared to the control group, but a third dose of the vaccine was found to be safe and significantly improved humoral immunity against SARS-CoV-2.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization

Guy Witberg et al.

Summary: Among 2.5 million patients who received the BNT162b2 mRNA vaccine in a large Israeli health care system, the incidence of myocarditis at 42 days was 2.13 cases per 100,000 persons, with the highest incidence (10.69 per 100,000 persons) among male patients between the ages of 16 and 29 years. Most cases of myocarditis were mild or moderate.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

D. Mevorach et al.

Summary: The incidence of myocarditis increased after receiving the BNT162b2 vaccine in Israel, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021

Anne M. Hause et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Kate-Lynn Muir et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer

Jerald Sadoff et al.

Summary: The manufacturer responds to recent reports of thrombosis and severe thrombocytopenia in recipients of the Ad26.COV2.S vaccine.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight US Locations, December 2020-March 2021

Mark G. Thompson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Prabhu S. Arunachalam et al.

Summary: The study found that vaccination with the Pfizer-BioNTech mRNA vaccine can induce immune responses against neutralizing antibodies and CD4, CD8 T cells of SARS-CoV-2. Booster vaccines can significantly enhance innate immune responses, and different innate pathways associated with CD8 T cells and neutralizing antibodies have been identified.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

M. G. Thompson et al.

Summary: A study with a test-negative design analyzed 41,552 admissions to 187 hospitals and 21,522 visits to 221 EDs or urgent care clinics. The mRNA-based vaccines (>= 14 days after the second dose) were highly effective against SARS-CoV-2 infection leading to hospitalization (89%), ICU admission (90%), or an urgent care visit (91%).

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Yinon M. Bar-On et al.

Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021

Shaun J. Grannis et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Wesley H. Self et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Biology

Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis

Tyler Wagner et al.

ELIFE (2020)

添加到收藏夹

Article Health Policy & Services

A Modification of the Elixhauser Comorbidity Measures Into a Point System for Hospital Death Using Administrative Data

Carl van Walraven et al.

MEDICAL CARE (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.